THERAPY DOSSIER · th-c3d285b58d0d

IL-17A neutralising monoclonal antibody, with 4-phenylbutyrate and TAK-242 as additional arms

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Endotoxin/LPS
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: anti-IL-17A monoclonal antibody; secukinumab; ixekizumab; 4-phenylbutyrate; TAK-242
Note: Not recorded

Clinical trials 10

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT04717466 ↗PHASE4completed

Brain Morphological Changes Accompanied by Effective Biologic Treatments for Psoriasis (secukinumab)

Psoriasis · Healthy

Enrolment: 20 · Results not recorded

NCT02662985 ↗PHASE3completed

Time Course of Response to Secukinumab on Joint Inflammation in Active Psoriatic Arthritis

Psoriatic Arthritis

Enrolment: 166 · Results not recorded

NCT03478787 ↗PHASE3completed

Risankizumab Compared to Secukinumab for Moderate to Severe Plaque Psoriasis

Psoriasis

Enrolment: 327 · Results not recorded

NCT02584855 ↗PHASE3completed

Long-Term Efficacy and Safety of Ixekizumab 80 mg Every 2 Weeks in bDMARD-Naive Patients With Active Psoriatic Arthritis

Psoriatic Arthritis

Enrolment: 394 · Results not recorded

NCT02763111 ↗PHASE2completed

BCD-085 (Anti-IL-17) in Patients With Active Ankylosing Spondylitis

Ankylosing Spondylitis

Enrolment: 88 · Results not recorded

NCT03099538 ↗PHASE2completed

Ixekizumab in the Treatment of Bullous Pemphigoid

Bullous Pemphigoid

Enrolment: 4 · Results not recorded

NCT05344248 ↗PHASE1/PHASE2completed

JS005 (Recombinant Humanized Anti-IL-17A Monoclonal Antibody) in Moderate to Severe Plaque Psoriasis

Moderate to Severe Psoriasis

Enrolment: 183 · Results not recorded

NCT03099980 ↗EARLY_PHASE1completed

Cosentyx (Secukinumab) for Patients With Moderate-to-Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa

Enrolment: 20 · Results not recorded

NCT04259346 ↗PHASE1completed

Bioequivalence of an Alternate Ixekizumab Formulation Compared to the Commercial Formulation in Healthy Subjects

Healthy

Enrolment: 245 · Results not recorded

NCT03828643 ↗Phase not recordedcompleted

Secukinumab Efficacy Without the Initial Loading Dose in Chronic Plaque Psoriasis

Psoriasis Vulgaris

Enrolment: 156 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 26516372 ↗2015Reported benefit

Blockade of Interplay between IL-17A and Endoplasmic Reticulum Stress Attenuates LPS-Induced Lung Injury.

MouseEndotoxin/LPSC57BL/6Femalen = 5 or 6 mice in each groupAnti-IL-17A intraperitoneal; 4-phenylbutyrate intraperitoneal; TAK-242 intravenousAnti-IL-17A 5 mg/kg body weight per day; 4-phenylbutyrate 2…Anti-IL-17A 6 h before and 6 h after LPS; 4-phenylbutyrate 1 h before and 6, 18…

Model: Single intratracheal instillation of 50 micrograms lipopolysaccharide in 50 microlitres saline under inhaled isoflurane anaesthesia

Anti-IL-17A antibody and 4-phenylbutyrate each reduced LPS-induced bronchoalveolar inflammatory cell influx, vascular leakage, myeloperoxidase activity, histological and micro-CT abnormalities, ER stress markers, NLRP3 inflammasome activation, TLR4 expression, dendritic cell infiltration and nuclea…

Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…